According to CNBC Drug-maker Bayer, agreeing to the largest divestiture in American antitrust enforcement history, will sell agricultural businesses and assets worth about $9 billion to chemical giant BASF, clearing the way for approval of its $66 billion acquisition of Monsanto, the Justice Department announced Tuesday.
The assets include Bayer’s canola, soybean and vegetable seed businesses, as well as its Liberty herbicide business, all of which currently compete with Monsanto products.
The Justice Department, in revealing the settlement it reached with Bayer, said the sell-off will “preserve competition threatened by Bayer’s acquisition of Monsanto.” Without the divestiture, the department said, the “merger is unlawful.”
Germany-based Bayer and St. Louis-based Monsanto are two of the world’s biggest agricultural companies, and currently compete against one another to sell farmers seed and crop protection products, the department noted. BASF is the largest chemical producer in the world.
Bayer still is awaiting approval from the governments of Canada and Mexico for the tie-up. The company has until June 14 to close its purchase of Monsanto. After that, Monsanto has the right to withdraw from the deal or ask for a higher price.
Full Content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas